Taken together, our data suggested that simultaneously blocking ERα signaling by ERα antagonist and KDM5C activity by KDM5C inhibitor is an effective way to suppress ERα‐positive breast cancer cell and tumor growth. This evidence concerns the gene ESR1 and breast carcinoma.